NASDAQ$VRCA
Verrica Pharmaceuticals Inc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
Verrica Pharmaceuticals reported Q3 2025, revenue of $3.6M, net loss of $274K.
For Q3 2025, Verrica Pharmaceuticals reported revenue of $3.6M, a net loss of $274K. Management discusses operations, liquidity, and outlook in the quarterly filing.
- Revenue $3.6M.
- Net loss $274K.
- Verrica Pharmaceuticals MD&A covers cash runway, pipeline, and sector risks.
Headline financials
Revenue & EPS history
Verrica · Revenue · Quarterly
$14.3M
Forward guidance
Clinical-stage biotech outlook centers on trial milestones, partnerships, and cash runway.
Tailwinds
- Pipeline progress and R&D prioritization.
- Cash and equivalents fund operations.
Headwinds
- Trial delay or failure risk.
- Potential dilution from future financings.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2025
-2.7%
Avg return
Earnings day
-3.4%
Avg return
5 days after
-1.1%
Avg return
30 days after
42%
13 / 31 earnings
Positive
+18.6%
Q1 2024
Best reaction
-47.9%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.8% | -15.3% | -19.9% | |
| Q4 2025 | +4.7% | +3.2% | -14.5% | |
| Q3 2025 | +3.2% | +15.8% | +104.7% | |
| Q1 2025 | +2.9% | -0.8% | -3.0% | |
| Q4 2024 | -7.6% | +0.5% | -25.3% | |
| Q3 2024 | -47.9% | -45.8% | -22.2% | |
| Q2 2024 | -44.8% | -43.8% | -62.6% | |
| Q1 2024 | +18.6% | +8.4% | +7.3% | |
| Q4 2023 | -3.0% | -10.1% | +3.5% | |
| Q3 2023 | -13.6% | -17.7% | +7.6% | |
| Q2 2023 | +7.6% | +1.6% | -18.5% | |
| Q1 2023 | -1.4% | -7.1% | -13.9% | |
| Q4 2022 | -6.9% | +1.5% | -21.6% | |
| Q3 2022 | -3.1% | +3.1% | +43.7% | |
| Q2 2022 | +17.1% | +9.6% | +18.8% | |
| Q1 2022 | -1.6% | -7.8% | -63.0% | |
| Q4 2021 | +1.3% | -7.7% | +1.9% | |
| Q3 2021 | -4.2% | -5.9% | -22.2% | |
| Q2 2021 | -1.6% | -0.7% | +12.6% | |
| Q1 2021 | -0.8% | -0.2% | -14.8% | |
| Q4 2020 | -9.6% | -0.2% | +1.3% | |
| Q3 2020 | +13.9% | +13.1% | +32.3% | |
| Q2 2020 | +5.6% | +4.8% | +29.6% | |
| Q1 2020 | +10.5% | +2.8% | +24.0% | |
| Q4 2019 | -12.1% | -7.5% | +31.3% | |
| Q3 2019 | +0.8% | +4.0% | -7.3% | |
| Q2 2019 | +2.6% | -9.3% | -2.3% | |
| Q1 2019 | +1.0% | -3.3% | -23.4% | |
| Q4 2018 | -7.5% | +1.1% | -8.0% | |
| Q3 2018 | -3.8% | +5.6% | -22.7% | |
| Q2 2018 | -0.9% | +2.7% | +13.8% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro